THYmine 2
| Full title: | An observational study to assess the ability of the thymine loading test to prospectively categorise patients with gastrointestinal or breast cancer who cannot tolerate fluoropyrimidine treatment |
| Cancer type: | Gastrointestinal and Breast |
| Status: | 166 participants recruited | No longer recruiting | Data cleaning and statistical analysis phase |
|
Brief description:
|
This study builds upon the first THYMINE Study. The primary objective is to assess the ability of the thymine loading test to prospectively categorise patients who cannot tolerate fluoropyrimidine treatment, in a wider patient cohort. Our second objective is to compare the thymine test to the predictive ability of a panel of known deleterious SNP in the DPYD gene. Thirdly we will look at using freshly collected buccal mucosal cells to assess inter-individual differences in 5-FU transmembrane uptake, and determine if high uptake is also associates with risk of 5-FU toxicity. |
| Sites: | Auckland City Hospital, Tauranga, Dunedin, Canopy Cancer Care (Auckland), Christchurch |
| Lead Investigator: | Associate Professor Nuala Helsby |
| Contact: | Eibhlin Corrigan (eibhlin.corrigan@auckland.ac.nz) |
| Sponsor: | University of Auckland |
| Funder: | Health Research Council of New Zealand, Gut Cancer Foundation |
| ClinicalTrials.gov reference: | ACTRN12617001109392 (click for more details) |
| Ethics number: | 17/CEN/149 |
| Publications: | Helsby N, Burns K, Findlay M, Porter D, Strother M. Testing for dihydropyrimidine dehydrogenase deficiency in New Zealand to improve the safe use of 5-fluorouracil and capecitabine in cancer patients. New Zealand Medical Journal. 2021;134(1545):106-114 |